popular posts
-
For all those involved in the vaccines' field, either operating within the industry or as simple observers, the last few years hav...
-
In a previous post I expressed my confidence that we would see a Gene Therapy product approved by either the EMA or the FDA by 2020 ...it t...
-
Maintaining a healthy pipeline and a steady revenue stream are on the top of the priority list for pharma and biotech companies. 2013 has ...
-
I have been extremely busy the past few months but eventually managed to find some time to finalize this Excel model, which allows you to a...
-
Despite not making any big headlines, a very important development took place in early December 2011: the very first Gene Therapy treatment ...
archive
-
►
2013
(
2
)
- ► September 2013 ( 1 )
- ► February 2013 ( 1 )
-
►
2012
(
5
)
- ► September 2012 ( 1 )
- ► August 2012 ( 1 )
- ► April 2012 ( 2 )
- ► January 2012 ( 1 )
-
►
2011
(
8
)
- ► November 2011 ( 1 )
- ► August 2011 ( 1 )
- ► April 2011 ( 1 )
- ► March 2011 ( 1 )
- ► February 2011 ( 2 )
- ► January 2011 ( 1 )
Disclaimer
I currently work at a Strategy Consulting firm supplying services to various pharmaceutical and biotechnology companies. The views expressed in this website are my own. I am not speaking officially for, or representing in any way, any company or corporation.
Timos Papagatsias, Ph.D.
You can connect with me on LinkedIn here and you can follow me on Twitter here.
You can also join my LinkedIn groups: Gene Therapy Network, Life Sciences Investment Network, Life Sciences/Pharmaceuticals/Biotechnology Consulting and AIDS/HIV Vaccine.
Visited BioHive so far...
© 2014
BioHive
All Rights Reserved. Designed By
MyThemeShop
. Blogger Theme by
BlogTipsNTricks
and
Right Blog Tips
.